Spain has updated its official series on the financing of innovative medicines, adding a third moving cohort and new analysis of products that require more than one financing procedure after an initial negative decision.
The Ministry of Health (Ministerio de Sanidad, MS) published Financiación de medicamentos innovadores en España(Financing of innovative medicines in Spain) on 24 June 2026. The report covers 221 innovative medicines authorised centrally in the EU between 1 January 2021 and 31 December 2024, excluding vaccines, generics and biosimilars. The data cut-off was 30 April 2026. (
The new report follows a first analysis published in May 2025 and an update in February 2026. The first report covered medicines authorised between January 2020 and December 2023. The February update covered July 2020 to June 2024. The June report moves the window forward again, to January 2021 to December 2024. MS notes that the cohorts overlap substantially, so changes between them are gradual rather than step changes.
Across the three cohorts, the financing rate has changed little. The proportion of EU-authorised medicines financed in Spain was 63.8% in the first cohort, 64.8% in the second and 64.7% in the third. Among medicines registered in Spain, the corresponding figures were 75.9%, 78.8% and 76.5%. The main movement is therefore in timing. Median time from EU authorisation to financing fell from 544 days in the first cohort to 503 days in the second and 474 days in the third. The median time from Spanish registration to financing fell from 431 days to 408 days and then 400 days.
The Ministry also gives more detail on Spain’s early-access route through Medicines in Special Situations (Medicamentos en Situaciones Especiales, MSE). In the third cohort, 122 of the 221 EU-authorised medicines, or 55.2%, had MSE access. Among registered medicines with MSE access, 78.9% ultimately obtained positive financing. The June report adds a further new indicator: 15.4% of financed medicines required a second or later financing procedure after an initial negative decision.
The official figures can be read against EFPIA’s 2025 Patients W.A.I.T. Indicator, but the two sources are not measuring exactly the same population. EFPIA covered 168 centrally authorised innovative medicines from 2021 to 2024 and measured availability as of 5 January 2026. For Spain, EFPIA recorded 116 available products, equivalent to 69%, and a median time to availability of 537 days. EFPIA defines Spanish availability as access on the public reimbursement list and notes that its analysis does not identify earlier access under Royal Decree 1015/2009 for MSE.
The direction of the two datasets is broadly consistent: Spain sits among the higher-availability European markets, while access still commonly takes well beyond the 180-day procedural benchmark. The added value of the MS series is that it is an official national dataset and separates successive stages of the Spanish pathway: EU authorisation, Spanish registration, financing decision, MSE access and repeat financing procedures. It therefore provides a more detailed basis for tracking whether recent Spanish pharmaceutical reforms are shortening the national financing stage, rather than only confirming whether a medicine appears on the reimbursement list.
Source: Ministry of Health
Link: Financiación de medicamentos innovadores en España (Financing of innovative medicines in Spain)
Date: 24 June 2026
